Sinoway Industrial Co., Ltd.

Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2 Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

  • CAS No. of key intermediates:
    • 124750-51-2
    • 144690-92-6
    • 80841-78-7
    • 144689-93-0
  • EINECS No.: 422-310-9
  • Type: Pharmaceutical Intermediates
  • Purity:99.0%
  • Application: Pharmaceutical Intermediates
  • Appearance: Off white to white crystalline powder
  • B.P:>320℃
  • Density:1.1

Usage of Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

  • Antihypertensive drugs are ACEI class (Puli), ARB (sartan), calcium antagonists (terrestrial), diuretics, B receptor blocker, a drug treatment is not good when the two Even a variety of combination, in the application of drug treatment should be combined with diet and exercise therapy.
  • The recommended dose is 80 mg once daily, regardless of gender, age and race. Antihypertensive effect occurred within 2 weeks, reaching the maximum after 4 weeks. In patients who do not have adequate blood pressure control, the daily dose may be increased to 160 mg or diuretics may be added. The drug can be combined with other anti-hypertensive agents.
  • No need to adjust dose in patients with mild to moderate renal impairment or in patients with non-biliary and non-biliary cirrhosis.
  • Elderly patients do not need to adjust the dose.
  • No safety and efficacy data are available for pediatric patients.
  • Hypertensive patients taking this medicine, blood pressure does not affect the heart rate.
  • Suddenly discontinued when the drug does not appear blood pressure rebound and other clinical adverse reactions.
  • Multi-dose taking this medicine on total cholesterol, fasting triglycerides, fasting blood glucose and uric acid no significant effect.

COA of Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

Product name

2-Cyano-4'-methylbiphenyl

Appearance

Off white or white crystalline powder

M.F

C14H11N

M.W

193.24

Boling point

>320 degree C

Melting point

49 degree C

Flash point

>320 degree C

Heavy mental

20 ppm max

Purity

99%min

Application

Pharmaceutical intermediate

Assay

99% min



MORE_DETAIL Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

Basic information of Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

  • CAS No. of key intermediates:
    • 124750-51-2
    • 144690-92-6
    • 80841-78-7
    • 144689-93-0
  • EINECS No.: 422-310-9
  • Type: Pharmaceutical Intermediates
  • Purity:99.0%
  • Application: Pharmaceutical Intermediates
  • Appearance: Off white to white crystalline powder
  • B.P:>320℃
  • Density:1.1

Usage of Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

  • Antihypertensive drugs are ACEI class (Puli), ARB (sartan), calcium antagonists (terrestrial), diuretics, B receptor blocker, a drug treatment is not good when the two Even a variety of combination, in the application of drug treatment should be combined with diet and exercise therapy.
  • The recommended dose is 80 mg once daily, regardless of gender, age and race. Antihypertensive effect occurred within 2 weeks, reaching the maximum after 4 weeks. In patients who do not have adequate blood pressure control, the daily dose may be increased to 160 mg or diuretics may be added. The drug can be combined with other anti-hypertensive agents.
  • No need to adjust dose in patients with mild to moderate renal impairment or in patients with non-biliary and non-biliary cirrhosis.
  • Elderly patients do not need to adjust the dose.
  • No safety and efficacy data are available for pediatric patients.
  • Hypertensive patients taking this medicine, blood pressure does not affect the heart rate.
  • Suddenly discontinued when the drug does not appear blood pressure rebound and other clinical adverse reactions.
  • Multi-dose taking this medicine on total cholesterol, fasting triglycerides, fasting blood glucose and uric acid no significant effect.

COA of Sartan Intermediate 7148-03-0/114772-34-8/114772-54-2/124750-51-2

Product name

2-Cyano-4'-methylbiphenyl

Appearance

Off white or white crystalline powder

M.F

C14H11N

M.W

193.24

Boling point

>320 degree C

Melting point

49 degree C

Flash point

>320 degree C

Heavy mental

20 ppm max

Purity

99%min

Application

Pharmaceutical intermediate

Assay

99% min


Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//